1. 2021
  2. Longitudinal assessment of lipoprotein(A) levels in perinatally HIV-infected children and adolescents

    van Genderen, J. G., van den Hof, M., de Boer, C. G., Jansen, H. P. G., van Deventer, S. J. H., Tsimikas, S., Witztum, J. L., Kastelein, J. J. P. & Pajkrt, D., 1 Oct 2021, In: Viruses. 13, 10, 2067.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. 25 years of anti-TNF treatment for inflammatory bowel disease: Lessons from the past and a look to the future

    D'Haens, G. R. & van Deventer, S., 1 Jul 2021, In: Gut. 70, 7, p. 1396-1405 10 p., gutjnl-2019-320022.

    Research output: Contribution to journalReview articleAcademic

  4. Secreted therapeutics: monitoring durability of microRNA-based gene therapies in the central nervous system

    Sogorb-Gonzalez, M., Vendrell-Tornero, C., Snapper, J., Stam, A., Keskin, S., Miniarikova, J., Spronck, E. A., de Haan, M., Nieuwland, R., Konstantinova, P., van Deventer, S. J., Evers, M. M. & Vallès, A., 2021, In: Brain Communications. 3, 2, p. fcab054

    Research output: Contribution to journalArticleAcademicpeer-review

  5. 2020
  6. Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain

    Depla, J. A., Sogorb-Gonzalez, M., Mulder, L. A., Heine, V. M., Konstantinova, P., van Deventer, S. J., Wolthers, K. C., Pajkrt, D., Sridhar, A. & Evers, M. M., 11 Sep 2020, In: Molecular therapy. Methods & clinical development. 18, p. 167-175 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. 2019
  8. AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes

    Keskin, S., Brouwers, C. C., Sogorb-Gonzalez, M., Martier, R., Depla, J. A., Vallès, A., van Deventer, S. J., Konstantinova, P. & Evers, M. M., 2019, In: Molecular therapy. Methods & clinical development. 15, p. 275-284

    Research output: Contribution to journalArticleAcademicpeer-review

  9. Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared with Healthy Ethnicity-Matched Controls

    van den Hof, M., Haneveld, M. J. K., Blokhuis, C., Scherpbier, H. J., Jansen, H. P. G., Kootstra, N. A., Dallinga-Thie, G. M., van Deventer, S. J. H., Tsimikas, S., Pajkrt, D., van den Hof, M., Blokhuis, C., Cohen, S., Pajkrt, D., Scherpbier, H. J., Kuijpers, T. W., van der Plas, A., Weijsenfeld, A., ter Stege, J. S., Kootstra, N. A., & 12 othersCaan, M. W. A., Mutsaerts, H. J. M. M., Majoie, C. B. L. M., Verbraak, F. D., Schmand, B., Geurtsen, G., Mathot, R. A. A., Wit, F. W. N. M., Reiss, P., Teunissen, C. E., Kuhle, J. & Meijer, J. C. M., 2019, In: Open forum infectious diseases. 6, 9, p. ofz301 ofz301.

    Research output: Contribution to journalArticleAcademicpeer-review

  10. 2016
  11. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses

    van Capelleveen, J. C., Kastelein, J. J. P., Zwinderman, A. H., van Deventer, S. J. H., Collins, H. L., Adelman, S. J., Round, P., Ford, J., Rader, D. J. & Hovingh, G. K., 2016, In: Journal of clinical lipidology. 10, 5, p. 1137-1144.e3

    Research output: Contribution to journalArticleAcademicpeer-review

  12. 2015
  13. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

    Hovingh, G. K., Kastelein, J. J. P., van Deventer, S. J. H., Round, P., Ford, J., Saleheen, D., Rader, D. J., Brewer, H. B. & Barter, P. J., 2015, In: Lancet. 386, 9992, p. 452-460

    Research output: Contribution to journalArticleAcademicpeer-review

  14. 2014
  15. Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver

    Maczuga, P., Verheij, J., van der Loos, C., van Logtenstein, R., Hooijer, G., Martier, R., Borel, F., Lubelski, J., Koornneef, A., Blits, B., van Deventer, S., Petry, H. & Konstantinova, P., 2014, In: Gene therapy. 21, 1, p. 60-70

    Research output: Contribution to journalArticleAcademicpeer-review

  16. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

    Ford, J., Lawson, M., Fowler, D., Maruyama, N., Mito, S., Tomiyasu, K., Kinoshita, S., Suzuki, C., Kawaguchi, A., Round, P., Boyce, M., Warrington, S., Weber, W., van Deventer, S. & Kastelein, J. J. P., 2014, In: British journal of clinical pharmacology. 78, 3, p. 498-508

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1 2 3 4 5 6 7 8 ...36 Next

ID: 95713